Targeting Hypertension with the Peregrine System™ Infusion Catheter using Dehydrated Alcohol Injection, USP
The Peregrine System™ Infusion Catheter uses proprietary, patented technology to deliver diagnostic and therapeutic agents directly to the perivascular space that surrounds blood vessels. The Peregrine System™ Infusion Catheter (Peregrine Catheter) is Medical Device Regulation (MDR) European Union (EU) 2017/745 CE Marked and is available in two models. The Peregrine Catheter 4-7 mm is intended for use in vessels having an inner diameter of 4-7 mm and the Peregrine Catheter 3-4 mm is intended for use in vessels having an inner diameter of 3-4 mm. The Peregrine System™ Infusion Catheter is intended for use in an alcohol-mediated renal denervation procedure. The Peregrine System™ Infusion Catheter delivers Dehydrated Alcohol Injection, USP (a neurolytic agent, also referred to as alcohol) into the perivascular space of renal arteries to ablate the sympathetic nerve fibers in the adventitial layer, and along the axis of the renal artery. The neurolytic effect on the renal sympathetic nerves results in a lowering of the patient’s blood pressure.
Hypertension
Peregrine System Infusion Catheter
The alcohol-mediated renal denervation procedure is performed using the Peregrine Catheter, which is designed to deliver Dehydrated Alcohol Injection, USP (a neurolytic agent, also referred to as alcohol) in the perivascular space of the renal artery to ablate the nerves known to influence the body’s regulation of blood pressure.
Clinical Trial Program
The ASI Clinical Trial program is investigating Dehydrated Alcohol Injection, USP injected using the Peregrine Catheter to assess the efficacy and safety of this alcohol-mediated renal denervation procedure to treat uncontrolled hypertension.